EUVIMEDEUVIMED entdecken
Crossref

Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy

Citradewi Soemardy iD, Yan-Ruide Li iD, Yichen Zhu, Xinyuan Shen, Lili Yang, Dino Di Carlo iD

ACS Nano · 2026

DOI: 10.1021/acsnano.5c22721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Citradewi Soemardy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of California, Los Angeles, California 90095, United States. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Neoplasms, Nanotechnology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Silicon Valley Community Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unconventional T cells, including mucosal-associated invariant T (MAIT) cells and invariant natural killer T (iNKT) cells, recognize nonpeptide antigens presented by MR1 and CD1d, respectively, and offer unique therapeutic potential. Despite invariant TCRα chains, diversity in TCRβ regions may underlie unique sequence-to-function relationships. Here, we develop a nanovial-based functional screening platform for the high-throughput discovery of TCRs from unconventional T cells present in human blood. By labeling nanovials with MR1 or CD1d molecules and cytokine-capture antibodies, we enable antigen-specific capture, activation, cytokine secretion, and oligobarcode-linked identification. Using secretion-encoded single-cell sequencing, we isolate rare MAIT and iNKT cells and associate their TCR identities with functional phenotypes. All five MAIT TCRs conferred antigen-specific cytokine secretion and cytotoxicity in vitro, with the two tested in vivo demonstrating tumor targeting, intratumoral accumulation, and measurable antitumor activity. Our nanotechnology-enabled "function-first" screen unlocks precision TCR discovery for unconventional T cells and supports the development of therapies targeting aberrant metabolic pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellNeoplasmsNanotechnologyHumansAnimalsMucosal-Associated Invariant T CellsMiceNatural Killer T-Cells

Stichwörter der Autor:innen

T-cell receptor (TCR) screeningcancer therapyinvariant natural killer T (iNKT) cellmucosal-associated invariant T (MAIT) cellnanovialunconventional T cell

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Bioengineering, University of California, Los Angeles, California 90095, United States.
  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, California 90095, United States.
  • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California 90095, United States.
  • Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, California 90095, United States.
  • Parker Institute for Cancer Immunotherapy, University of California, Los Angeles, California 90095, United States.
  • California NanoSystems Institute (CNSI), University of California, Los Angeles, California 90095, United States.

ORCID-Profile: Citradewi Soemardy, Yan-Ruide Li, Dino Di Carlo

Förderung

  • Silicon Valley Community Foundation

Zitieren

APA

Soemardy, C., Li, Y. R., Zhu, Y., Shen, X., Yang, L., & Di Carlo, D. (2026). Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy. ACS Nano. https://doi.org/10.1021/acsnano.5c22721

Vancouver

Soemardy C, Li YR, Zhu Y, Shen X, Yang L, Di Carlo D. Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy. ACS Nano. 2026. doi:10.1021/acsnano.5c22721

BibTeX
@article{Soemardy2026,
  author = {Soemardy, Citradewi and Li, Yan-Ruide and Zhu, Yichen and Shen, Xinyuan and Yang, Lili and Di Carlo, Dino},
  title = {Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.5c22721}
}
Kostenlos starten →